title: Hepatitis C treatment: interferon free or interferon freer?
authors.affiliation: UCL Institute of Liver and Digestive Disease, Royal Free Hospital, London NW3 2PF, UK. g.dusheiko@ucl.ac.uk
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Dusheiko
authors.forename: Tabinda
authors.initials: T
authors.lastname: Burney
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage; D012254:Ribavirin / Q000008:administration & dosage*; D000069474:Sofosbuvir; D014542:Uridine Monophosphate / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D014542:Uridine Monophosphate; C100416:peginterferon alfa-2a; D000069474:Sofosbuvir